Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.31 -0.42 (-3.3%) Market Cap: 540.19 Mil Enterprise Value: 484.06 Mil PE Ratio: 0 PB Ratio: 5.45 GF Score: 56/100

Y-mAbs Therapeutics, Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 03:00PM GMT
Release Date Price: $50.27 (-3.25%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome everyone to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Y-mAbs, and speaking on behalf of the company, we have CEO, Claus Møller. Before I turn it over to Claus, I just want to remind those on the webcast that you can submit a question via the ask the question feature in the portal, and I'm happy to ask a question on your behalf.

With that, I'll turn it over to you, Claus.

Claus Juan MÃ;ller San Pedro
Y-mAbs Therapeutics, Inc. - CEO & Director

¸ -

Thank you very much, Anupam, and thank you, everybody, for listening into today to our company presentation for the JPMorgan Conference, January 2021. You should have access to the slide deck, and I'm going to go to the disclaimer and make sure that you have all paid attention to that. Our mission in Y-mAbs is to become the world leader in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot